Search research articles
Contact Us
Filters
Showing results (431-440 of 481) with videos related to
Page
of 49
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 11, 2017
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper
Matti Aapro, Alain Astier, Riccardo Audisio, et al.
The Lancet. Oncology
|
June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron, James P Morden, Peter Canney, et al.
Frontiers in Cellular and Infection Microbiology
|
July 3, 2020
Differences in Compositions of Gut Bacterial Populations and Bacteriophages in 5-11 Year-Olds Born Preterm Compared to Full Term
Thilini N Jayasinghe, Tommi Vatanen, Valentina Chiavaroli, et al.
Lancet (London, England)
|
January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D Gelber, et al.
Breast Cancer Research and Treatment
|
January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron, Michelle Casey, Michael Press, et al.
Journal of Leukocyte Biology
|
June 13, 2020
Targeting NLRP3 and Staphylococcal pore-forming toxin receptors in human-induced pluripotent stem cell-derived macrophages
Seong H Chow, Pankaj Deo, Amy T Y Yeung, et al.
Ebiomedicine
|
May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
Sylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
The Lancet. Oncology
|
August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron, Julia Brown, Rebecca Dent, et al.
Clinical Pharmacology and Therapeutics
|
August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial
Enora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)
Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Page
of 49
Search research articles
Search
Showing results (431-440 of 481) with videos related to
Sort By:
Page
of 49
European Journal of Cancer (Oxford, England : 1990)
|
July 11, 2017
Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper
Matti Aapro, Alain Astier, Riccardo Audisio, et al.
The Lancet. Oncology
|
June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
David Cameron, James P Morden, Peter Canney, et al.
Frontiers in Cellular and Infection Microbiology
|
July 3, 2020
Differences in Compositions of Gut Bacterial Populations and Bacteriophages in 5-11 Year-Olds Born Preterm Compared to Full Term
Thilini N Jayasinghe, Tommi Vatanen, Valentina Chiavaroli, et al.
Lancet (London, England)
|
January 9, 2007
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D Gelber, et al.
Breast Cancer Research and Treatment
|
January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron, Michelle Casey, Michael Press, et al.
Journal of Leukocyte Biology
|
June 13, 2020
Targeting NLRP3 and Staphylococcal pore-forming toxin receptors in human-induced pluripotent stem cell-derived macrophages
Seong H Chow, Pankaj Deo, Amy T Y Yeung, et al.
Ebiomedicine
|
May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial
Sylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
The Lancet. Oncology
|
August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron, Julia Brown, Rebecca Dent, et al.
Clinical Pharmacology and Therapeutics
|
August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial
Enora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)
Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Page
of 49